RxDoctor Payments DataLook up a doctor →

Joseph Owens, MD

Neurology · Prestonsburg, KYNPI 1508010505

Payments from drug & device makers

$140,831in general payments, 2019–2025

Across 742 payments — averaging $189.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$54K
  • Amgen$25K
  • Teva Pharmaceuticals USA, Inc.$22K
  • Biohaven Pharmaceuticals, Inc.$19K
  • Biohaven Pharmaceutical Holding Company Ltd.$14K
  • UCB, Inc.$2K
  • plus $5K from 36 others

What the payments were for

  • Consulting fees$4000%
  • Speaking & faculty fees$127,85491%
  • Travel & lodging$1,3311%
  • Food & beverage$11,2398%
  • Education$70%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$140,831 in reported general payments places this provider in the 90th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$53,579
Medicare patients
317
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RebifInterferon Beta-1a/Albumin12$120,958
CopaxoneGlatiramer Acetate19$92,955
VumerityDiroximel Fumarate11$87,715
QuliptaAtogepant75$85,944
UbrelvyUbrogepant65$68,700
Nurtec OdtRimegepant Sulfate23$43,077
Aimovig AutoinjectorErenumab-Aooe49$35,594
VimpatLacosamide23$28,009
NeuproRotigotine32$26,119
Tetrabenazine23$24,810
NourianzIstradefylline12$21,880
Glatiramer Acetate12$21,235
Tiagabine Hcl24$14,314
Emgality PenGalcanezumab-Gnlm19$14,025
Ajovy AutoinjectorFremanezumab-Vfrm19$12,941

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$54,419$154,645140 claims
EMD Serono, Inc.Rebif$111$120,95812 claims
Teva Pharmaceuticals USA, Inc.Copaxone$21,684$92,95519 claims
BiogenVumerity$1,601$87,71511 claims
UCB, Inc.Vimpat, Neupro$1,623$54,12755 claims
PfizerNurtec Odt$399$43,07723 claims
Kyowa Kirin, Inc.Nourianz$135$21,88012 claims
Upsher-smith Laboratories LLCTopiramate$13$4,937107 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$14$2,95556 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 210 neurology providers in Kentucky.

Other neurology in Prestonsburg

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →